Characterization and Therapeutic Application of the ICOS Receptor To Treat Peripheral T-Cell Lymphoma
ISEF · 2024 Cellular and Molecular Biology Third Award
Overview
Peripheral T-cell lymphoma (PTCL) is a rare and aggressive non-Hodgkin lymphoma resulting from clonal proliferation of mature post-thymic T-cells. The mechanisms behind PTCL development and progression remains incompletely understood, which explains the lack of successful targeted immunotherapies. The inducible T-cell co-stimulator (ICOS), a member of the CD28 superfamily, has shown to be upregulated in PTCL, which makes it a worthy target of further investigation. This study investigated the role of ICOS in regulating the mechanisms of PTCL by examining cytokine release, cellular proliferation, and ICOS expression in two cutaneous T-cell lymphoma (CTCL) cell lines upon induced ICOS activation. The results highlight that ICOS activation independent of T-cell receptor co-engagement induces potent secretion of IFN?, and that ICOS activation directly inhibits CTCL cell proliferation in vitro. Additionally, this study validated ICOS as an effective therapeutic candidate for an antibody-drug conjugate (ADC) by demonstrating the internalization capability of the ICOS receptor upon activation via flow cytometry. Lastly, this study validated the efficacy of an anti-ICOS ADC in vitro; an ADC targeting ICOS potentiated killing of 40% of CTCL tumor volume over a 3-day period. These findings indicate that an anti-ICOS ADC could be highly effective at killing malignant PTCL cells that express ICOS. Anti-ICOS monoclonal antibodies by themselves may also inhibit tumor growth in CTCL. Ultimately, this study elucidates the vital role ICOS plays in regulating PTCL tumor growth and signaling, and provides rationale for an immunotherapy which could markedly enhance antitumor efficacy in ICOS-positive PTCLs.
Awards (1)
- Third Award of $1,000 $1,000
Competition history
- ISEF 2024
Resources
Related projects
ISEF · 2018
BIC Augments the Proliferative Effects of miR-155 in Diffuse Large B Cell Lymphoma Via Downregulation of Tumor Suppressor and Anti-Apoptotic Targets
ISEF · 2015
Novel Treatment Strategy for Chronic Lymphocytic Leukemia: Malignant B1 Cell Depletion via Siglec-10 Stimulation
ISEF · 2025
Computational Modeling of Bispecific Antibodies Targeting CD30+ Cells in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
ISEF · 2024
Small Molecule Stabilization of the CARD11 G-quadruplex Represses Transcription: Developing a Therapeutic Target for Diffuse Large B-Cell Lymphoma
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair